RE:Lowering expectations on efficacy???Perplexingly, he saved the harder sell on cancer until the end, where he brought up some new stuff and really got more animated about the opportunity. The preliminary efficacy data, however, was not highlighted or re-affirmed for before the end of the year. But we did get:
1.) Partnership incancer being pursued in China.
2.) Dosing weekly versus every three weeks in cancer
3.) Acknowledgement that they will be partnering in cancer generally
He pushed hard on NASH but still made no mention of the comparison to IVA's or AKRO's market caps versus TH's. I struggle to see why a CEO who apparently believes he has sommethign better than the others (first to market, best to market comments) would not highlight ALL DAY LONG how his stock is not getting any credit for what they have in NASH versus other stocks that are getting a whole lot of credit. And when you consider they are in need of money to get that program launched, it makes even less sense.
qwerty22 wrote: Not strong.
Also. He's clearly not prep'd to talk on market opportunity.